Document is current
Any future updates will be listed below
-
Authors
Pizzamiglio, S.
Blanda, A.
Appierto, V.
Minicozzi, P.
Carnevale, M. G.
De Santis, M. C.
Re, B.
Cortesi, L.
Gasparini, E.
Arpino, G.
Giuliano, M.
Molinaro, V.
Iorio, M. V.
De Cecco, L.
Bertolotti, A.
Brich, S.
Vingiani, Andrea
De Marco, C.
Pruneri, G.
Verderio, P.
Di Cosimo, S.
-
Funding
Funding for this research was provided by:
Ministry of Health, Ricerca Corrente funds
- License Information
-
More Information
Article History
Received: 7 August 2025
Accepted: 16 November 2025
First Online: 3 December 2025
Competing interests
: G.P.: speaker honoraria/advisory board: ADS Biotec, Exact Sciences, Lilly, Novartis, and Roche; institutional research grant from Roche; L.C.: speaker bureau: AstraZeneca, MSD, Pfizer, Novartis, Gilead, Roche, Daiichi Sankyo; advisory board: AstraZeneca, MSD, Novartis; travel and accommodation expenses from Gilead, Pfizer, Daiichi Sankyo; S.D.C.: “ad hoc” medical monitor for Medica Scientia Innovation Research (MEDSIR), Barcelona (Spain); as well as support for attending meetings and/or travel from Daiichi Sankyo, and participation in an advisory board for Pfizer. M.G.: speaker honoraria/advisory board: AstraZeneca, Daichii Sankyo, Eisai, Exact Sciences, Gilead, Gentili, Lilly, MSD, Novartis, Pfizer, Roche. G.A.: honoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational events from Roche, Pfizer, Lilly, AstraZeneca, Novartis and Gilead; travel grants from Roche, Lilly, AstraZeneca and Gilead; advisory boards for Roche, Novartis, Lilly, Pfizer, MSD, Dompè, Pierre Fabre, Eisai, Sophos, Epionpharma, Gilead, Seagen, Astra Zeneca and Exact Science. P.V. and S.D.C. are leading the PNRR-POC-2023-12378113 project, founded by the European Union - Next Generation EU – PNRR M6C2 – Investimento 2.1 Valorizzazione e potenziamento della ricerca biomedical del SSN, titled “A Composite Assay for HER2- Positive Early-Stage Breast Cancer Management”. The authors declare no competing interests.
